Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2013 Jul;22(7):927-32. doi: 10.1517/13543784.2013.801958. Epub 2013 May 21.

PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.

Author information

1
Clinical Research Unit Head, University of Cape Town, University of Cape Town Lung Institute, Centre for Tuberculosis Research Innovation, Division of Pulmonology, Department of Medicine, Cape Town, South Africa. rodney.dawson@uct.ac.za

Abstract

INTRODUCTION:

New treatment regimens are urgently required for tuberculosis (TB). The existing four-drug regimen for TB is > 20 years old, with multidrug resistant (MDR) and extensively drug-resistant (XDR) TB on the increase.

AREAS COVERED:

Recently, the first novel potential combination TB treatment regimen for both drug-sensitive and MDR TB incorporating a new nitroimidazole compound, PA-824 , was investigated in a Phase II proof-of-concept clinical trial. This article reviews the rationale for this novel study, discusses the development strategy for PA-824 and highlights the study findings and its implications for future development of this regimen.

EXPERT OPINION:

Expert opinion will be offered on the utility of this new multicomponent treatment regimen. We will highlight how this study informs the development pathway for future novel TB regimens and explore the PA-824, moxifloxacin (MOX) and pyrazinamide combination as a first step towards developing a single treatment regimen for both drug-sensitive and drug-resistant diseases.

PMID:
23687915
DOI:
10.1517/13543784.2013.801958
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center